Skip to main content
TARA
NASDAQ Life Sciences

Protara Q3 Loss Widens to $21.7M; Buys Novex Manufacturing Assets for $8.75M

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Neutral
Importance info
7
Price
$2.11
Mkt Cap
$125.873M
52W Low
$2.11
52W High
$7.82
52W Position info
0.0% above low
Off High info
73% below high
Rel. Volume info
0.6× avg
Market data snapshot near publication time

TARA is trading near its 52-week low of $2.11 (0.0% above the low).

Summary

Protara posted a wider Q3 loss of $21.7 million, with $143.1 million in cash funding operations into 2028. Separately, it agreed to buy TARA-002 manufacturing assets from Novex for $8.75 million while pushing STARBORN-1 enrollment into early 2027.


Key Events · Earnings and Guidance · TARA

  • Q3 Loss Widens on Higher R&D

    Net loss of $21.7 million, or $0.35 per share, versus $13.3 million, or $0.31 per share, a year earlier; R&D rose to $16.8 million from $9.6 million.

  • Cash Runway Into 2028

    Unrestricted cash, equivalents and marketable debt securities totaled $143.1 million as of September 30, 2026, down from $161.9 million at June 30.

  • Novex Manufacturing Asset Purchase

    On November 4, 2026, Protara agreed to buy TARA-002 manufacturing-related assets from Novex Innovations for $8.75 million, including workforce, inventory, IP, equipment and a facility lease.

  • STARBORN-1 Enrollment Slips to 1Q 2027

    Enrollment in the registrational STARBORN-1 trial in lymphatic malformations is now expected to complete early in 1Q 2027, with a rolling BLA submission in 2H 2027.


Analysis · TARA · Life Sciences

Protara's Q3 net loss widened to $21.7 million from $13.3 million a year ago, with R&D spending jumping to $16.8 million from $9.6 million on higher trial costs. Cash and investments of $143.1 million are still expected to fund operations into 2028, so there is no near-term financing emergency. The more consequential item is the $8.75 million purchase of TARA-002 manufacturing assets from Novex, its clinical supply partner since 2019 — bringing production in-house ahead of a potential launch. Against that, the STARBORN-1 lymphatic malformation trial now completes enrollment in early 1Q 2027 rather than by year-end 2026, a slip that pushes the rolling BLA to 2H 2027.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, TARA was trading at $2.11 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $125.9M. The 52-week trading range was $2.11 to $7.82. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

TARA - Latest Insights

TARA
Nov 06, 2026, 8:00 AM EST
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $2.11
Real-time Price: $2.28 info
Change: +$0.170 (+8%) info
Market Cap: $140.38M info
TARA
Aug 11, 2026, 8:10 AM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $3.98
Real-time Price: $2.28 info
Change: -$1.70 (-43%) info
Market Cap: $140.38M info
TARA
Aug 11, 2026, 8:05 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $3.98
Real-time Price: $2.28 info
Change: -$1.70 (-43%) info
Market Cap: $140.38M info
TARA
Aug 11, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $3.98
Real-time Price: $2.28 info
Change: -$1.70 (-43%) info
Market Cap: $140.38M info
TARA
Jul 01, 2026, 4:10 PM EDT
Filing Type: 4
Importance Score:
8
Price at Filing: $4.04
Real-time Price: $2.28 info
Change: -$1.76 (-44%) info
Market Cap: $140.38M info